Clinical Trials Logo
  1. Home
  2. Generalized Anxiety Disorder
  3. NCT00711737
  4. Details
NCT00711737 Clinical Trial

Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Generalized Anxiety Disorder Clinical Trial

Official title:
Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00711737
Other study ID # 2008.06
Secondary ID
Status Completed
Phase N/A
First received July 8, 2008
Last updated June 15, 2011
Start date September 2008
Est. completion date October 2010

Study information
Verified date June 2011
Source Changi General Hospital
Contact n/a
Is FDA regulated No
Health authority Singapore: Health Sciences Authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.

Description:

This is an open-label study, with 4 scheduled visits. Recruitment of 100 subjects. Assessments include demographics, diagnosis, smoking frequency, Clinical Global Scale (CGI-S), weight, height,blood pressure, waist and hip circumference and fasting blood glucose and lipd profile.

Statistical analysis will be exploratory and mainly descriptive.

Recruitment information / eligibility
Status Completed
Enrollment 27
Est. completion date October 2010
Est. primary completion date October 2010
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Give informed consent

- Requires pharmacological treatment with escitalopram for major depression, generalized anxiety disorder or panic disorder

- Aged 21 years old and above

- Able to comprehend and comply with protocol

- Not pregnant and if of child-bearing age, using adequate methods of contraception

Exclusion Criteria:

- Currently taking or has taken in previous 3 months, any other antidepressants, antipsychotics, mood stabilizers, weight loss or lipid-profile modifying drugs

- Contraindications to escitalopram

- Unstable medical illness and/or is already under treatment of diabetes, hypertension, dyslipidemia, ischemic heart disease

- History of non-response to escitalopram

- Meets IDF definition of metabolic syndrome

- Significant risk of suicide

- Primary diagnosis or comorbid diagnosis of psychotic disorder, bipolar disorder, substance dependence and/or dementia

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Singapore Changi General Hospital Singapore

Sponsors (1)
Lead Sponsor Collaborator
Changi General Hospital

Country where clinical trial is conducted

Singapore, 

See also
  Status Clinical Trial Phase
Terminated NCT03420456 - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Withdrawn NCT02382224 - Worry Exposure for Generalized Anxiety Disorder N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT02306356 - Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting N/A
Completed NCT01958788 - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder N/A
Completed NCT01681329 - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder N/A
Completed NCT01342120 - PHARMO Institute Seroquel Safety Study N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT01337713 - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD) N/A
Completed NCT00961298 - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Phase 4
Completed NCT01203293 - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector Phase 1
Completed NCT01971203 - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat N/A
Completed NCT00744627 - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. Phase 3
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00515242 - Therapeutic Massage for Generalized Anxiety Disorder Phase 1/Phase 2
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00537615 - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers Phase 1
Completed NCT00368745 - Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. Phase 3
Completed NCT00620776 - Combined Treatment for Generalized Anxiety Disorder (GAD) Phase 2